[
    {
        "content": "* Q3 revenue $291.6 million versus i/b/e/s view $285.5 million",
        "date": "10262017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Bioverativ reports Q3 earnings per share $0.63 "
    },
    {
        "content": "* Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 -- a gene-edited cell therapy candidate -- to treat beta-thalassemia",
        "date": "10022017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 "
    },
    {
        "content": "* Bioverativ and Bicycle Therapeutics enter into strategic research collaboration to develop therapies for haemophilia and sickle cell disease",
        "date": "09062017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Bioverativ and Bicycle Therapeutics enter into strategic research collaboration "
    },
    {
        "content": "* Q2 earnings per share view $0.71 -- Thomson Reuters I/B/E/S",
        "date": "08022017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Bioverativ reports Q2 GAAP earnings per share $0.71 "
    },
    {
        "content": "* Valueact Capital Management LLC reports 3.8 percent stake in Bioverativ Inc as of July 13 versus 7.5 percent stake as of Feb 28 - SEC filing Source text:(http://bit.ly/2u29MGC) Further company coverage:",
        "date": "07172017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Valueact Capital Management LLC reports 3.8 pct stake in Bioverativ Inc as of July 13 - SEC filing "
    },
    {
        "content": "* Bioverativ inc - on june 28  entered into a credit agreement by and among bioverativ and certain subsidiaries as borrowers - sec filing",
        "date": "06292017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Bioverativ says on June 28  entered into a credit agreement "
    },
    {
        "content": "* Bioverativ announces FDA acceptance of investigational new drug application for BIVV001  a novel  long-acting FVIII hemophilia therapeutic utilizing amunix XTEN\u00ae half-life extension technology",
        "date": "06142017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Amunix Operating Inc says FDA has accepted Bioverativ's IND application for BIVV001 "
    },
    {
        "content": "* Bioverativ announces FDA acceptance of investigational new drug application for BIVV001 to treat hemophilia A",
        "date": "06122017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Bioverativ announces FDA acceptance of investigational new drug application for BIVV001 "
    },
    {
        "content": "* BIOVERATIV ACQUIRES HBM-PORTFOLIO COMPANY TRUE NORTH THERAPEUTICS FOR UP TO USD 825 MILLION PLUS ASSUMED CASH Source text - http://bit.ly/2qgeVHB Further company coverage: (Gdynia Newsroom)",
        "date": "05232017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-HBM Healthcare Investments: Bioverativ acquires HBM-portfolio company True North Therapeutics "
    },
    {
        "content": "* Bioverativ to acquire clinical-stage rare disease biotechnology company  True North Therapeutics",
        "date": "05232017",
        "name": "Bioverativ Inc",
        "news_type": "normal",
        "symbol": "BIVV",
        "title": "BRIEF-Bioverativ to acquire True North Therapeutics "
    },
    {
        "content": "* Bioverativ appoints Geno J. Germano to company's board of directors",
        "date": "05152017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Bioverativ appoints Geno J. Germano to company's board "
    },
    {
        "content": "* Q1 REVENUE $259.1 MILLION VERSUS I/B/E/S VIEW $247.1 MILLION",
        "date": "05032017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-BIOVERATIV Q1 GAAP EARNINGS PER SHARE $0.64 "
    },
    {
        "content": "* Healthcor Management reports a 5.1 percent passive stake in  bioverativ inc as of April 4 Source text for Eikon: (http://bit.ly/2ocN2ip) Further company coverage:",
        "date": "04132017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Healthcor Management reports a 5.1 pct passive stake in  Bioverativ Inc "
    },
    {
        "content": "* Bioverativ Inc - Appointment brings Bioverativ's total number of directors to five  four of whom are independent  Source text for Eikon: Further company coverage:",
        "date": "03022017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Anna Protopapas to join Bioverativ board of directors "
    },
    {
        "content": "* Valueact Capital Management Lp reports 7.1 percent stake in Bioverativ Inc as of Feb 6 - SEC filing",
        "date": "02172017",
        "name": "Bioverativ Inc",
        "news_type": "topStory",
        "symbol": "BIVV",
        "title": "BRIEF-Valueact Capital reports 7.1 pct stake in Bioverativ "
    }
]